Navigation Links
Drug Shows Promise in Nervous-System Tumor Treatment
Date:7/8/2009

In small study, some patients had their hearing restored

WEDNESDAY, July 8 (HealthDay News) -- U.S. researchers report the first successful drug treatment of tumors in patients with neurofibromatosis type 2 (NF2).

In people with NF2, benign tumors develop throughout the nervous system. The most common tumor is a vestibular schwannoma, which grows on the nerve connecting the ear to the brain. This type of tumor, also called acoustic neuroma, causes hearing loss and can press on the brain stem, leading to serious neurologic symptoms and the risk of death.

Currently, these tumors are treated with surgery or radiation. This study found that treatment with the angiogenesis inhibitor bevacizumab (Avastin) shrank vestibular schwannomas, improved hearing and eased other symptoms in NF2 patients.

Bevacizumab is an anti-cancer drug designed to reduce blood flow to tumors in order to shrink them. But the drug wasn't used on acoustic neuromas because it was believed that they didn't stimulate formation of new blood vessels, as malignant tumors do.

But researchers at Massachusetts General Hospital in Boston analyzed tissue samples of NF2-related vestibular schwannomas and found evidence of excess blood vessel development. They then decided to test bevacizumab in 10 NF2 patients with vestibular schwannomas.

Tumor shrinkage occurred in nine patients, six of whom had a 20 percent or greater reduction in tumor size. The tumor shrinkage lasted between 11 and 16 months. Of the seven patients who had started to lose their hearing before treatment, four had some hearing restored. This improvement also lasted for up to 16 months.

"This kind of treatment response is unprecedented," lead author Dr. Scott Plotkin of the Pappas Center for Neuro-Oncology in the MGH Cancer Center, said in a news release. "Our study is the first to provide evidence that a drug can shrink vestibular schwannomas…and the first to show that patients' hearing can be improved."

The study will appear online in advance of publication in the July 23 issue of the New England Journal of Medicine.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more about neurofibromatosis.



-- Robert Preidt



SOURCE: Massachusetts General Hospital, news release, July 8, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Study shows endoscopic surgery as effective open surgery for nasal cancer
2. Independent Laboratory Testing Shows BioNeutrals Hospital Grade Ygiene(TM) Eliminates Aspergillus Niger (Black Mold) Spores
3. CU-Boulder study shows brains immune system may cause chronic seizures
4. New Study Shows Daily Sex Can Increase Sperm Count
5. Study shows PET can measure effectiveness of novel breast cancer treatment
6. New Study Shows Many Unplanned Quit Smoking Attempts are Successful
7. Police work undermines cardiovascular health, comparison to general population shows
8. Study shows 1 in 25 deaths worldwide attributable to alcohol
9. National Survey Shows 70% of Women Have Experienced a Sexual Health Issue
10. Girls Overall Self-Worth Improves With Contact Lens Wear, Study Shows
11. New Study Shows that Prebiotics, as Used by Jackson GI Medical, Increases Lifespan by 33%
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Shows Promise in Nervous-System Tumor Treatment 
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset ... of specialty vendors and unique items from across the nation, this holiday-themed event will ... services offered by the VNA. The boutique will be open Saturday, November 4 ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the ... today its plans to open a flagship location in Covington, LA at 401 N. ... To Go store next to Office Depot in the Holiday Square shopping center. Its ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite ... program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... of 2017 on Tuesday, October 24, 2017. Lilly will ... the investment community and media to further detail the ... begin at 9 a.m. Eastern time. Investors, media and ... the conference call through a link that will be ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, Inc. ... earnings conference call and webcast on Friday, November 3, ... (EDT) and ending at approximately 8:30 a.m. (CDT) / ... the company,s 2017 financial performance and guidance for 2018, ... initiatives to enhance operational performance, and long-range financial outlook ...
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
Breaking Medicine Technology: